Brain Activity of Benzoate, a D-Amino Acid Oxidase Inhibitor, in Patients With Mild Cognitive Impairment in a Randomized, Double-Blind, Placebo Controlled Clinical Trial

BACKGROUND: Current anti-dementia drugs cannot benefit mild cognitive impairment (MCI). Sodium benzoate (a D-amino acid oxidase [DAO] inhibitor) has been found to improve the cognitive function of patients with early-phase Alzheimer’s disease (mild Alzheimer’s disease or MCI). However, its effect on...

Descripción completa

Detalles Bibliográficos
Autores principales: Lane, Hsien-Yuan, Tu, Cheng-Hao, Lin, Wei-Che, Lin, Chieh-Hsin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Regular Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130199/
https://www.ncbi.nlm.nih.gov/pubmed/33406269
http://dx.doi.org/10.1093/ijnp/pyab001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130199/
https://www.ncbi.nlm.nih.gov/pubmed/33406269
http://dx.doi.org/10.1093/ijnp/pyab001

Ejemplares similares